Fibroblast growth factor 1 alleviates diabetic nephropathy by reducing renal lipid accumulation in diabetic kidney

Figure 7 Fibroblast growth factor 1 reduces lipid accumulation in high glucose and palmitate acid-treated human kidney-2 cells by enhancing fatty acid beta-oxidation. A: Triglyceride content measured to assess lipid accumulation in high glucose and palmitate acid-treated human kidney-2 cells with or without fibroblast growth factor 1 and etomoxir treatment; B: Lipid deposition visualized by Oil Red O staining; C: Quantification of Oil Red O staining; D: Adipose differentiation related protein (ADRP) expression evaluated by immunofluorescence; E: Quantification of ADRP immunofluorescence; F: ADRP protein expression detected by Western blot; G: Quantification of Western blot results. Three to four independent experiments were performed for each analysis. Data were presented as mean ± SD. ^aP < 0.05. ADPR: Adipose differentiation related protein; Ctrl: Control; Etomoxir: A high selective inhibitor of carnitine palmitoyl transferase 1A; FGF1: Fibroblast growth factor 1; HGPA: High glucose and palmitic acid.